Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives
Open Access
- 18 January 2021
- journal article
- review article
- Published by LLC "Medical Knowledge and Technologies" in Tuberculosis and Lung Diseases
- Vol. 98 (12) , 57-66
Abstract
The article presents a review of 70 publications. It describes relevant data on drugs, timing, indications, efficacy, and safety of short-term treatment regimens for multiple drug resistant tuberculosis.Keywords
This publication has 44 references indexed in Scilit:
- Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015European Respiratory Journal, 2017
- Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European UnionEuropean Respiratory Journal, 2017
- Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: a prospective cohort study from urban ChinaEuropean Respiratory Journal, 2017
- Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysisThe Lancet Respiratory Medicine, 2017
- Target regimen profiles for treatment of tuberculosis: a WHO documentEuropean Respiratory Journal, 2017
- Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosisThe Lancet Respiratory Medicine, 2016
- Successful ‘9-month Bangladesh regimen’ for multidrug-resistant tuberculosis among over 500 consecutive patientsThe International Journal of Tuberculosis and Lung Disease, 2014
- Multidrug-Resistant Tuberculosis and Culture Conversion with BedaquilineNew England Journal of Medicine, 2014
- Sterilizing Activity of Second-Line Regimens Containing TMC207 in a Murine Model of TuberculosisPLOS ONE, 2011
- Combinations of R207910 with Drugs Used To Treat Multidrug-Resistant Tuberculosis Have the Potential To Shorten Treatment DurationAntimicrobial Agents and Chemotherapy, 2006